S
Stephen R. Rapp
Researcher at Wake Forest University
Publications - 243
Citations - 19020
Stephen R. Rapp is an academic researcher from Wake Forest University. The author has contributed to research in topics: Dementia & Cognition. The author has an hindex of 55, co-authored 212 publications receiving 16715 citations. Previous affiliations of Stephen R. Rapp include Pfizer & United States Department of Veterans Affairs.
Papers
More filters
Journal ArticleDOI
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Sally A. Shumaker,Claudine Legault,Stephen R. Rapp,Leon J. Thal,Robert B. Wallace,Judith K. Ockene,Susan L. Hendrix,Beverly N. Jones,Annlouise R. Assaf,Rebecca D. Jackson,Jane Morley Kotchen,Sylvia Wassertheil-Smoller,Jean Wactawski-Wende +12 more
TL;DR: Estrogen plus progestin therapy increased the risk for probable dementia in postmenopausal women aged 65 years or older and did not prevent mild cognitive impairment in these women, supporting the conclusion that the risks of estrogen plus progESTin outweigh the benefits.
Journal ArticleDOI
Psoriasis causes as much disability as other major medical diseases.
TL;DR: Different aspects of psoriasis are related to the different dimensions of HRQL supporting the need for multidimensional treatment models, similar to that of other major medical diseases.
Journal ArticleDOI
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study
Sally A. Shumaker,Claudine Legault,Lewis H. Kuller,Stephen R. Rapp,Leon J. Thal,Dorothy S. Lane,Howard Fillit,Marcia L. Stefanick,Susan L. Hendrix,Cora E. Lewis,Kamal Masaki,Laura H. Coker +11 more
TL;DR: Estrogen therapy alone did not reduce dementia or MCI incidence and increased the risk for both end points combined and use of hormone therapy to prevent dementia or cognitive decline in women 65 years of age or older is not recommended.
Journal ArticleDOI
Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Stephen R. Rapp,Mark A. Espeland,Sally A. Shumaker,Victor W. Henderson,Robert L. Brunner,JoAnn E. Manson,Margery Gass,Marcia L. Stefanick,Dorothy S. Lane,Jennifer Hays,Karen C. Johnson,Laura H. Coker,Maggie Dailey,Deborah J. Bowen +13 more
TL;DR: Among postmenopausal women aged 65 years or older, estrogen plus progestin did not improve cognitive function when compared with placebo, and timing of prior hormone therapy initiation with respect to the final menstrual period did not affect the results.
Journal ArticleDOI
Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative memory study: a randomized clinical trial ☆
TL;DR: Estrogen plus progestin therapy increased the risk for probable dementia in postmenopausal women aged 65 years or older and did not prevent mild cognitive impairment in these women, supporting the conclusion that the risks of estrogen plus progESTin outweigh the benefits.